公开(公告)号：US5980881A

公开(公告)日：1999-11-09

申请号：US812129

申请日：1997-03-05

申请人： Masayuki Mitsuka ,  Hiroshi Shimada ,  Mizue Kawai

发明人： Masayuki Mitsuka ,  Hiroshi Shimada ,  Mizue Kawai

IPC分类号： A61K31/787 ,  A61K31/785

CPC分类号： A61K31/787

摘要： A medicament for preventive and/or therapeutic treatment of hyperphosphatemia which comprises a pharmaceutically acceptable anion exchange resin such as a 2-methylimidazole/epichlorohydrin copolymer, cholestyramine resin, or colestipol. The medicament is orally available and has lowering effect on blood phosphate concentration and reducing effect on urinary phosphate excretion, and is useful for the treatment of conditions caused by hyperphosphatemia including renal dysfunction and the like.

摘要翻译： 一种用于预防和/或治疗高磷酸血症的药物，其包含药学上可接受的阴离子交换树脂，例如2-甲基咪唑/表氯醇共聚物，考来烯胺树脂或考来替泊。 该药物可口服，对血磷酸盐浓度降低，对尿磷酸盐排泄有减少作用，可用于治疗高磷血症，包括肾功能不全等引起的病症。

公开(公告)号：US5807860A

公开(公告)日：1998-09-15

申请号：US748612

申请日：1996-11-13

申请人： Shinya Inoue ,  Masao Taniguchi ,  Yoshihiro Tarao ,  Kazuo Suzuki ,  Chizuko Takahashi ,  Mizue Kawai ,  Masayuki Mitsuka

发明人： Shinya Inoue ,  Masao Taniguchi ,  Yoshihiro Tarao ,  Kazuo Suzuki ,  Chizuko Takahashi ,  Mizue Kawai ,  Masayuki Mitsuka

IPC分类号： C07D207/32 ,  C07D207/325 ,  C07D213/30 ,  C07D295/092 ,  C07D521/00 ,  A61K31/495 ,  A61K31/53 ,  C07D241/02 ,  C07D403/02

CPC分类号： C07D207/325 ,  C07D213/30 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D295/088

摘要： A compound represented by formula (I) and a salt thereof, and a hydrate and solvate thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 represent independently, for example, hydrogen atom, hydroxyl group, or C.sub.1-3 alkoxy group; R.sub.4 represents, for example, C.sub.1-7 alkyl group or C.sub.3-7 cycloalkyl group; R.sub.5 and R.sub.6 represent independently, for example, hydrogen atom or C.sub.1-3 alkyl group; Y represents C.sub.1-3 alkyl group, a heterocyclic group containing 1 to 4 nitrogen atoms and 5 or 6 ring-membered atoms, or C.sub.6-10 aryl group; k represents an integer of 1 to 3; and l represents an integer of 2 to 4. These urea compounds have excellent inhibitory activities against ACAT and are useful as active ingredients of medicines for preventive and/or therapeutic treatment of hyperlipemia and atherosclerosis.

摘要翻译： 由式（I）表示的化合物及其盐及其水合物和溶剂合物：其中R 1，R 2和R 3独立地表示例如氢原子，羟基或C 1-3烷氧基 ; R4表示例如C 1-7烷基或C 3-7环烷基; R5和R6独立地表示例如氢原子或C1-3烷基; Y表示C1-3烷基，含有1至4个氮原子和5或6个环原子的杂环基或C6-10芳基; k表示1〜3的整数， l表示2〜4的整数。这些脲化合物对ACAT具有优异的抑制活性，可用作预防和/或治疗高脂血症和动脉粥样硬化的药物的活性成分。

公开(公告)号：US5082856A

公开(公告)日：1992-01-21

申请号：US369816

申请日：1989-06-22

申请人： Masao Taniguchi ,  Kohei Umezu ,  Tadashi Shirasaka ,  Shinya Inoue ,  Tetsuro Shinpuku ,  Masayuki Mitsuka ,  Mayumi Hirata

发明人： Masao Taniguchi ,  Kohei Umezu ,  Tadashi Shirasaka ,  Shinya Inoue ,  Tetsuro Shinpuku ,  Masayuki Mitsuka ,  Mayumi Hirata

IPC分类号： C07D207/34

CPC分类号： C07D207/34

摘要： Novel pyrrolecarboxylic acid derivatives represented by the following formula: ##STR1## where R.sup.1 is a hydrogen atom, an alkyl group of 5 to 25 carbon atoms or an alkenyl group of 5 to 25 carbon atoms, R.sup.2 is a hydrogen atom, a phenyl group or an optionally substituted alkyl group of 1 to 10 carbon atoms, and R.sup.3 is a hydrogen atom, an alkyl group of 5 to 25 carbon atoms or an alkenyl group of 5 to 25 carbon atoms, or pharmaceutically acceptable salts thereof are provided.The compounds are highly effective in reducing the level of triglyceride or cholesterol in serum, and useful as an active ingredient of a pharmaceutical composition for treating hyperlipemia and arteriosclerosis.

公开(公告)号：USRE35096E

公开(公告)日：1995-11-21

申请号：US183744

申请日：1994-01-21

申请人： Masao Taniguchi ,  Kohei Umezu ,  Tadashi Shirasaka ,  Shinya Inoue ,  Tetsuro Shinpuku ,  Masayuki Mitsuka ,  Mayumi Hirata

发明人： Masao Taniguchi ,  Kohei Umezu ,  Tadashi Shirasaka ,  Shinya Inoue ,  Tetsuro Shinpuku ,  Masayuki Mitsuka ,  Mayumi Hirata

IPC分类号： C07D207/34 ,  A61K31/40 ,  A61P3/06 ,  C07D207/333

CPC分类号： C07D207/34

摘要： Novel pyrrolecarboxylic acid derivatives represented by the following formula: ##STR1## where R.sup.1 is a hydrogen atom, an alkyl group of 5 to 25 carbon atoms or an alkenyl group of 5 to 25 carbon atoms, R.sup.2 is a hydrogen atom, a phenyl group or an optionally substituted alkyl group of 1 to 10 carbon atoms, and R.sup.3 is a hydrogen atom, an alkyl group of 5 to 25 carbon atoms or an alkenyl group of 5 to 25 carbon atoms, or pharmaceutically acceptable salts thereof are provided.The compounds are highly effective in reducing the level of triglyceride or cholesterol in serum, and useful as an active ingredient of a pharmaceutical composition for treating hyperlipemia and arteriosclerosis.

摘要翻译： 由下式表示的新型吡咯羧酸衍生物：其中R 1是氢原子，5至25个碳原子的烷基或5至25个碳原子的烯基，R 2是氢原子，苯基或 可以具有取代基的碳原子数为1〜10的烷基，R3为氢原子，碳原子数为5〜25的烷基或碳原子数为5〜25的烯基，或其药学上可接受的盐。 该化合物在降低血清中甘油三酯或胆固醇水平方面是高度有效的，并且可用作治疗高脂血症和动脉硬化的药物组合物的活性成分。